... patients Survival Toxicity Multiple myeloma (MM) is a disease of the elderly with a median age at diagnosis of 74 years in women and 72 years in men in Germany [ 1 ]. The treatment of elderly MM patients is challenging because they are heterogeneous regarding comorbidities, fitness, activities...

... to the pivotal phase II and III trials. Methods: One hundred twenty-six patients with STS, treated by trabectedin between 2002 and 2019, were analyzed in this retrospective study, in two French centers. The effects of trabectedin on survival, response, and toxicity were described. All patients were tested...

...: The prevalence of sarcopenia was 40.23%. Sarcopenia did not influence dose-limiting toxicity of treatment, hazard ratio (HR) 1.01, 95% CI (0.70–1.47). Sarcopenia was associated with lower progression-free survival (PFS): HR 1.49, 95% CI (0.98–2.26), and lower overall survival (OS): HR 1.67, 95% CI (1.11–2.52...

...%. Grade 3–4 toxicities were 7.8% hypertension, 4.7% anemia, 3.1% mucositis, 3.1% asthenia, 1.6% diarrhea, 1.6% anorexia, 1.6% worsening of renal function, and 3.1% cardiac events. Dose reduction to 0.89 mg was applied to 17.2% of patients, and the discontinuation rate due to toxicity was 5.8%. Median...

... ) or MAPI regimen (MAP plus ifosfamide 9 g/m 2 ). We applied interval compression to MAPI by shortening the preoperative period to be aligned with that of MAP. Adjuvant chemotherapy was tailored according to the necrosis rate of resected tumor specimens. Necrosis rate, toxicity, and survival outcome were...

...: In this retrospective study, vinflunine treatment was well tolerated and resulted in a good level of disease control (complete response + partial response + stable disease >50%), with a manageable toxicity profile. The median PFS and OS were 3.2 and 6.8 months, respectively. A significant correlation between pain...

..., metro, and state levels. The association between age, gender, and race with type, frequency, and severity of treatment-emergent toxicities and clinical benefit was assessed using univariate and multivariable models. Results: Data from 117 eligible patients – Blacks/Caucasians/Others (27/85/5); male...

... to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role...

.... Despite the similar overall toxicity profile, cetuximab and panitumumab retain peculiar safety characteristics that deserve to be deeply investigated. Methods: We conducted a systematic review for randomized trials in PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science...

... included. CRT was well tolerated, with only 24.6% grade ≥3 acute toxicity. Overall, the 5-year OS, LFFS, LRFFS, and DMFS were 75.3, 60.2, 74.2, and 66.2%, respectively. Early complete clinical response and tumor stage at diagnosis were the strongest predictors of OS ( p = 0.04) and local failure ( p = 0.03...

.... This leads to uncertainty regarding the treatment of older patients with potentially toxic but active regimens. Methods: Using a prospectively generated database, we analyzed 63 patients aged ≥70 years undergoing perioperative chemotherapy for locally advanced esophagogastric cancer. The information included...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Prognosis Colon cancer Adjuvant chemotherapy Toxicity Colon cancer represents one of the most common causes of cancer and cancer-related death in Western countries...

...Piera Gargiulo; Laura Arenare; Carmela Pisano; Sabrina Chiara Cecere; Sara Falivene; Stefano Greggi; Rosa Tambaro; Gaetano Facchini; Giampaolo De Palma; Cono Scaffa; Chiara Della Pepa; Sandro Pignata; Marilena Di Napoli Objective: The aim of this study was to analyze the long-term toxicity...

... Tumors (RECISTv1.1) [ 33 ]. Toxicities were evaluated according to CTCAE v4.0. Neurotoxicity was not evaluated when patients did not claim any neurological complaints. Overall survival was measured from the date of the regimen initiation to the date of any cause of death or the last follow-up...

... of this study was to estimate the rate of adverse events in BRCA1/2 -associated breast cancer patients receiving anthracycline-based chemotherapy compared to patients without mutation. The authors also compared radiotherapy toxicity in these 2 groups. Methods: The analysis included 270 early-stage breast cancer...

... toxicities during treatment within oncology phase I trials of molecularly targeted agents where entry criteria mandate a serum creatinine of ≤1.5 × the upper limit of normal. Methods: Documented toxicity and creatinine clearance (calculated by the Cockcroft-Gault formula) from all patients treated...

.... Patients and Methods: From November 2005 to August 2008, 132 histologically confirmed advanced RCC patients (100 in the global expanded access program) were enrolled. Response and toxicity were assessed regularly according to the protocol. Results: Within this population, 82.6% had clear cell RCC, and 28.8...

...). Moreover, there were no statistical differences in median disease-free survival and overall survival between the groups. There was more hematologic toxicity in the IAP group (neutropenia, p = 0.002; thrombocytopenia, p = 0.001; febrile neutropenia, p < 0.001). Conclusions: The addition of ifosfamide...

... non-small cell lung cancer. Grade 3–4 thrombocytopenia and neutropenia are frequent. The aim of this study is to investigate whether toxicity of gemcitabine/carboplatin could be reduced by administering carboplatin on day 8 instead of day 1 without a decrease in response rate (RR). Methods: Patients...

...A.L. Jones; J. Holborn; S. Ashley; I.E. Smith In an attempt to achieve adequate palliation in patients with small cell lung cancer (SCLC) while keeping toxicity to a minimum, we compared CVM (car-boplatin/vinblastine/methotrexate) and standard therapy with ACE (doxoru-bicin/cyclophosphamide...